This is the authors' abstract. We don't add key points for this paper.
Background: The incidence of colorectal cancer (CRC) is rising, worldwide, and is attributed to genetics and epigenetic factors. We aimed to evaluate the key clinicodemographical/epidemiological-and molecular impacts on metastatic CRC in CRC patients from a highly populated area in northeastern Iran. Retrospective clinical materials-based cohort design and patients were analyzed with respect to age, sex, colorectum anatomy, metastasis, mortality as well as to expression of molecular markers B3GALNT2, mucin I ( MUC1), P53 and Ki67. Methods: Patients, 6260 registered CRC with 3829 underwent surgery, from three medical university hospitals in the study area, during 2006-2016, were analyzed for the clinicodemographic aspects of age, sex, stage of CRC, history of smoking, familial/occupational status and post-surgery survival period as well as mRNA/protein expression of B3GALNT2, MUC1, P53 and Ki67. Factors were set to estimate mortality and risk of metastatic CRC. Results: ~61%, ~33% and ~6% of adenocarcinomatous CRC were located in colon, rectum and rectosigmoid, respectively, of which younger-and older than 50 was mainly in transvers colon-and colorectum, respectively. Post-surgery survival period of metastatic CRC patients was remarkably longer in patients aged > 50 than those < 50 years old, and worse in females than males. B3GALNT2 high , MUC1 high , P53 low and Ki67 high mRNA/protein expression in metastatic stage III CRC were highly associated with increased metastasis and mortality. B3GALNT2 high , MUC1 high , P53 low and Ki67 high mRNA/protein expression correlated with increased risk of a progressed CRC state and mortality. The risk to develop metastatic CRC was higher in males, younger, urban residing-and employed individuals, indicative of a plausible non-genetics/epigenetics contribution to CRC. Conclusions: The role of possible diagnostic biomarkers, B3GALNT2, MUC1 and Ki67, but not P53, in the etiology/early detection of metastatic CRC is promising. Epigenetic contribution to metastatic CRC risk is predominant.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Ranjbary et al. (2019) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: